Unknown

Dataset Information

0

Evaluation of Pneumococcal Surface Protein A as a Vaccine Antigen against Secondary Streptococcus pneumoniae Challenge during Influenza A Infection.


ABSTRACT: Secondary bacterial pneumonia is responsible for significant morbidity and mortality during seasonal and pandemic influenza. Due to the unpredictability of influenza A virus evolution and the time-consuming process of manufacturing strain-specific influenza vaccines, recent efforts have been focused on developing anti-Streptococcus pneumoniae immunity to prevent influenza-related illness and death. Bacterial vaccination to prevent viral-bacterial synergistic interaction during co-infection is a promising concept that needs further investigation. Here, we show that immunization with pneumococcal surface protein A (PspA) fully protects mice against low-dose, but not high-dose, secondary bacterial challenge using a murine model of influenza A virus-S. pneumoniae co-infection. We further show that immunization with PspA is more broadly protective than the pneumococcal conjugate vaccine (Prevnar). These results demonstrate that PspA is a promising vaccine target that can provide protection against a physiologically relevant dose of S. pneumoniae following influenza infection.

SUBMITTER: Roberts S 

PROVIDER: S-EPMC6963301 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Evaluation of Pneumococcal Surface Protein A as a Vaccine Antigen against Secondary <i>Streptococcus pneumoniae</i> Challenge during Influenza A Infection.

Roberts Sean S   Williams Clare M CM   Salmon Sharon L SL   Bonin Jesse L JL   Metzger Dennis W DW   Furuya Yoichi Y  

Vaccines 20191011 4


Secondary bacterial pneumonia is responsible for significant morbidity and mortality during seasonal and pandemic influenza. Due to the unpredictability of influenza A virus evolution and the time-consuming process of manufacturing strain-specific influenza vaccines, recent efforts have been focused on developing anti-<i>Streptococcus pneumoniae</i> immunity to prevent influenza-related illness and death. Bacterial vaccination to prevent viral-bacterial synergistic interaction during co-infectio  ...[more]

Similar Datasets

| S-EPMC6386546 | biostudies-literature
| S-EPMC3859839 | biostudies-literature
| S-EPMC175255 | biostudies-other
| S-EPMC3428385 | biostudies-literature
| S-EPMC4762909 | biostudies-literature
| S-EPMC98401 | biostudies-literature
| S-EPMC3623503 | biostudies-literature
| S-EPMC5626202 | biostudies-other
| S-EPMC4097443 | biostudies-literature
| S-EPMC8492210 | biostudies-literature